Expert Point of View: Cabozantinib Broadly Active in Multiple Tumor Types

Get Permission

Mark Kris, MDMark G. Kris, MD, Chair of the ASCO Cancer Communications Committee, commented at the press briefing that the study represents “an example of the evolution of targeted cancer therapies in that we are seeing early signs of benefit by going after multiple targets in the cancer cell. We saw important tumor shrinkage that translated into stronger bones and less pain from bony metastases,” he said. ■

Financial Disclosure: Dr. Kris reported no potential conflicts of interest.

Related Articles

Cabozantinib Broadly Active in Multiple Tumor Types

Cabozantinib (XL184), an oral inhibitor of MET kinase and the vascular endothelial growth factor receptor (VEGFR2), produced high rates of disease control in several solid tumor types and controlled bone metastases in many patients, according to a phase II study presented at the 2011 ASCO Annual...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.